Acusphere bullish despite missing trial goal, enters pact with GE Healthcare
This article was originally published in Clinica
Executive Summary
Acusphere saw its share price drop this week, after announcing that a late-stage clinical trial of its ultrasound contrast agent for assessing blood flow to the heart muscle failed to meet one of its three goals.